Skip to content

Research highlights potential limits to ocriplasmin activity as a vitreolytic agent

New research, published in the journal Investigative Ophthalmology & Visual Science (IOVS), has highlighted potential variability and non-linear pharmacokinetics in the clinical response to a new enzymatic treatment (Ocriplasmin/Jetrea) for vitreo-macular adhesion (VMA). The research, published jointly by a number of academic centres and a private company, ThromboGenics NV (Euronext Brussels: THR), shows that ocriplasmin is highly autolytic in the vitreous. In addition, the research suggests that the duration of ocriplasmin’s enzymatic activity may vary based on the presence and concentration of serine protease inhibitors, potentially limiting ocriplasmin’s activity as a vitreolytic agent.